XENETIC BIOSCIENCES, INC. Letters of Credit Outstanding, Amount
XENETIC BIOSCIENCES, INC. (XBIO) had Letters of Credit Outstanding, Amount of $200.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Other Liabilities
us-gaap:LettersOfCreditOutstandingAmount · last filed 2026-03-12
- 2025-12-31: Letters of Credit Outstanding, Amount $200.00K.
- 2024-12-31: Letters of Credit Outstanding, Amount $100.00K.
| Period end | Letters of Credit Outstanding, Amount |
|---|---|
| 2025-12-31 | $200.00K 10-K · filed 2026-03-12 |
| 2024-12-31 | $100.00K 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |